Currently submitted to: JMIR Preprints
Date Submitted: Nov 24, 2025
Open Peer Review Period: Nov 24, 2025 - Nov 9, 2026
(currently open for review)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
The Longevity Revolution: How Artificial Intelligence is Challenging the Paradigm of Evolutionary Canalization
ABSTRACT
Classical evolutionary theory, notably Riedl’s concept of canalization, suggests that human lifespan is constrained by deeply entrenched developmental architectures, implying that aging is an immutable biological reality. However, rapid advancements in artificial intelligence (AI) from 2023 to 2025 have begun to challenge this pessimism. This viewpoint synthesizes recent developments to argue that AI is reframing aging from a biological mystery into a tractable engineering challenge. We examine two primary frontiers: the use of autonomous AI agents and generative models to discover geroprotective interventions, including the identification of compounds like ouabain via large-scale omics re-analysis; and the maturation of multi-modal “aging clocks” that utilize deep learning to enable precision diagnostics and personalized healthspan optimization. While acknowledging significant limitations regarding safety, translation from animal models, and the risks of commercial hype, we conclude that the integration of AI with mechanistic geroscience offers a plausible pathway toward a proactive, engineering-based approach to human longevity.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.